PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar ThePoulTrend (49.90) Submitted: 11/11/2011 9:28:19 AM : Outperform Start Price: $5.84 PDLI Score: -2.08

Serious Dividend!

Featured Broker Partners


Advertisement